key: cord-1008026-uwxvk1jy
authors: Pérez‐García, Felipe; Romanyk, Juan; Moya Gutiérrez, Helena; Labrador Ballestero, Andrea; Pérez Ranz, Inés; González Arroyo, Javier; González Ventosa, Victoria; Pérez‐Tanoira, Ramón; Domingo Cruz, Concepción; Cuadros‐González, Juan
title: Comparative evaluation of Panbio and SD Biosensor antigen rapid diagnostic tests for COVID‐19 diagnosis
date: 2021-05-31
journal: J Med Virol
DOI: 10.1002/jmv.27089
sha: 00d08404aa9c9b6a2cd5334f18700e3cd1058f58
doc_id: 1008026
cord_uid: uwxvk1jy

The aim of our study was to evaluate the diagnostic performance of two antigen rapid diagnostic tests (Ag‐RDTs) to diagnose severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) infection. We evaluated Panbio and SD‐Biosensor Ag‐RDTs. We employed 186 polymerase chain reaction (PCR) negative samples to evaluate the specificity and 170 PCR positive samples to assess the sensitivity. We evaluated their sensitivity according to Cycle threshold (C (t)) values and days post onset of symptoms (d.p.o.). Tests were compared using the McNemar's test. Agreement was evaluated using the kappa score. Specificity was 100% for Panbio and 97.3% for SD‐Biosensor. Sensitivity for samples with C (t )≤ 20 was 100% for both assays and for samples with C (t) = 20–25 was 93.0% (Panbio) and 95.3% (SD‐Biosensor) (p = 1.000). Sensitivity decreased for samples wit C (t) = 25–30 (Panbio: 41.3%, SD‐Biosensor: 52.2%, p = 0.125) and samples with C (t )≥ 30 (Panbio: 5.0%, SD‐Biosensor: 17.5%, p = 0.063). Sensitivity within seven d.p.o. was 87.7% for Panbio and 90.4% for SD‐Biosensor and notably decreased after seven d.p.o. Agreement with PCR was excellent for high viral load samples (C (t) ≤ 25): Panbio, 98.9%, kappa = 0.974; SD‐Biosensor, 97.4%, kappa = 0.940. Agreement between Ag‐RDTs was excellent (94.9%, kappa = 0.882). Panbio and SD‐Biosensor Ag‐RDTs showed excellent agreement and diagnostic performance results for samples with high viral loads (C (t )≤ 25) or samples within seven d.p.o.

The pandemic due to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has become one of the main global economic and health priorities. Viral RNA detection in respiratory samples using polymerase chain reaction (PCR) is the current reference method for coronavirus disease 2019 (COVID- 19) diagnosis. However, they are not useful as point of care (POC) tests due to an excessive turnaround time for results. 1, 2 Antigen rapid diagnostic tests (Ag-RDTs) have been developed as alternative tests to PCR for COVID-19 symptomatic patients, as they could be employed as POC tests, presented a lower cost than PCR assays and could improve the turnaround time for results. Moreover, some authors have shown that these advantages could overcome the sensitivity limitation, especially where PCR is unavailable or where prolonged turnaround times preclude clinical utility. [3] [4] [5] Our objective was to evaluate the diagnostic performance of two of these commercialized Ag-RTDs.

The study was performed between 1 and 30 December 2020. We included 356 nasopharyngeal samples, which were submitted in 3 ml of universal transport medium (UTM). Each sample corresponded to one single patient and we included 186 PCR negative samples and another 170 PCR positive samples. Table S1 ).

Regarding Ag-RDTs, we evaluated two Ag-RDTs that detected SARS-CoV-2 nucleoprotein antigens: Panbio COVID-19 Ag Rapid Test Device (Abbot Rapid Diagnostics GmbH, Jena) and SD-Biosensor STANDARD F COVID-19 Ag FIA (SD Biosensor, Inc.). Lecture of the results was optical for Panbio and by immunofluorescence using a STANDARD F2400 analyzer (SD Biosensor, Inc.) for SD-Biosensor Ag-RDT.

All equipments were used according to the manufacturer's instructions for both the handling and the interpretation of the results.

Clinical variables of the study population (time from the onset of symptoms) were obtained from the medical records. We assessed SARS-CoV-2 viral load using the Cycle threshold (C t ) value corresponding to N gene for all PCR positive samples. 6 

Categorical variables were expressed as proportions and continuous variables as median and interquartile range (IQR) and. Sensitivity and specificity with 95% confidence intervals (95% CI) were calculated using RT-PCR as gold standard. Sensitivity was evaluated globally and also according to the C t value for N gene 7 using different cutoffs 

Diagnostic performance results according C t values are summarized in Table 1 and Figure S1 . Specificity was 100% for Panbio and 97.3%

for SD-Biosensor, due to five PCR negative samples that were positive for this assay. Overall sensitivity was 60.0% for Panbio and 66.5%

for SD-Biosensor and this difference was statistically significant (p = 0.003). Sensitivity was higher for samples with high viral loads, reaching 100.0% for samples with C t ≤ 20 for both tests. For samples with C t = 20-25, sensitivity was 93.0% for Panbio and 95.3% for SD-Biosensor (p = 1.000). Sensitivity significantly decreased for low viral load samples: for C t values between 25 and 30, sensitivity was 41.3%

for Panbio and 52.2% for SD-Biosensor (p = 0.125), and for C t values over 30, sensitivity was 5.0% for Panbio and 17.5% for SD-Biosensor (p = 0.063). There were no significant differences on sensitivity results between Ag-RDTs according C t values (Table 1) Abbreviations: Ag-RDT, antigen rapid diagnostic test; C t , cycle threshold; N/A, not applicable; 95% CI, 95% confidence interval; p-value, level of significance.

T A B L E 2 Diagnostic performance of the evaluated Ag-RDTs according to time form the onset of symptoms 

In vitro diagnostic assays for COVID-19: recent advances and emerging trends

Considerations for diagnostic COVID-19 tests

Rethinking Covid-19 test sensitivity-a strategy for containment

Test sensitivity is secondary to frequency and turnaround time for COVID-19 surveillance. medRxiv. 2020

Antigen-detection in the diagnosis of SARS-CoV-2 infection using rapid immunoassays

Clinical course and molecular viral shedding among asymptomatic and symptomatic patients with SARS-CoV-2 infection in a community treatment center in the Republic of Korea

Panbio antigen rapid test is reliable to diagnose SARS-CoV-2 infection in the first 7 days after the onset of symptoms

Interrater reliability: the kappa statistic

Analytical and clinical performance of the panbio COVID-19 antigen-detecting rapid diagnostic test

Rapid, point-of-care antigen and molecular-based tests for diagnosis of SARS-CoV-2 infection

Evaluation of the Panbio Covid-19 rapid antigen detection test device for the screening of patients with Covid-19

Diagnostic performance of CerTest and Panbio antigen rapid diagnostic tests to diagnose SARS-CoV-2 infection

Urgent need of rapid tests for SARS CoV-2 antigen detection: evaluation of the SD-Biosensor antigen test for SARS-CoV-2

Evaluation of rapid antigen test for detection of SARS-CoV-2 virus

Evaluation of a rapid diagnostic assay for detection of SARS-CoV-2 antigen in nasopharyngeal swabs

Clinical Evaluation of Roche SD Biosensor Rapid Antigen Test for SARS-CoV-2 in Municipal Health Service Testing Site, the Netherlands. Emerging Infectious Diseases

Development and potential usefulness of the COVID-19 Ag Respi-Strip diagnostic assay in a pandemic context

COMMISSION RECOMMENDATION of 18.11.2020 on the use of rapid antigen tests for the diagnosis of SARS-CoV-2 infection

European Centre for Disease Prevention and Control. Options for the use of rapid antigen tests for COVID-19 in the EU/EEA and the UK. TECHNICAL REPORT

Recommendations for use of antigenic tests in the diagnosis of acute SARS-CoV-2 infection in the second pandemic wave: attitude in different clinical settings